NCT05178017View on ClinicalTrials.gov

Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
IBS - Irritable Bowel Syndrome
Interventions
DIAGNOSTIC_TEST

Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program

The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.

Trial Locations (1)

33404

Oxford Biomedical Technologies, Inc., Riviera Beach

Sponsors
All Listed Sponsors
lead

Oxford Biomedical Technologies, Inc.

INDUSTRY

NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) | Biotech Hunter | Biotech Hunter